Evidence-Based Medicine ; Humans ; Rhinitis, Allergic, Perennial ; drug therapy ; Rhinitis, Allergic, Seasonal ; drug therapy

Humans ; Pre-Exposure Prophylaxis ; methods ; Rhinitis, Allergic, Seasonal ; drug therapy ; Seasons

Objective:To observe the efficacy and safety of the M receptor antagonist Bencycloquidium bromide nasal spray in treatment of seasonal allergic rhinitis with runny nose as the main symptom. Methods:From August 2021 to September 2021, 134 patients with seasonal allergic rhinitis were enrolled in the otolaryngology Outpatient Department of Peking University Third Hospital, First Affiliated Hospital of Harbin Medical University and China-Japanese Friendship Hospital of Jilin University, including 71 males and 63 females, with a median age of 38 years. TNSS score and visual analogue scale（VAS） of total nasal symptoms were observed during 2 weeks of treatment with Bencycloquidium bromide nasal spray. Results:TNSS score decreased from （8.89±3.31） on day 0 to （3.71±2.51） on day 14（P<0.001）, VAS score of nasal symptoms decreased from （24.86±7.40） on day 0 to （6.84±5.94） on day 14（P<0.001）, VAS score of rhinorrhoea decreased from （6.88±2.06） on day 0 to （1.91±1.81） on day 14（P<0.001）. Rhinoconjunctivitis quality of life questionnaire（RQLQ） score decreased from （94.63±33.35） on day 0 to （44.95±32.28） on day 14（P<0.001）. The incidence of adverse reaction was low and no serious adverse events occurred during the whole experiment. Conclusion:Bencycloquidium bromide nasal spray has significant efficacy and good safety in the treatment of seasonal allergic rhinitis.
Male ; Female ; Humans ; Adult ; Rhinitis, Allergic, Seasonal/drug therapy* ; Nasal Sprays ; Quality of Life ; Administration, Intranasal ; Rhinorrhea ; Double-Blind Method ; Treatment Outcome ; Rhinitis, Allergic/drug therapy*

Acetates ; therapeutic use ; Child ; Child, Preschool ; Female ; Humans ; Leukotriene Antagonists ; therapeutic use ; Male ; Quinolines ; therapeutic use ; Rhinitis, Allergic, Perennial ; drug therapy ; Rhinitis, Allergic, Seasonal ; drug therapy ; Single-Blind Method

OBJECTIVETo observe the clinical efficacy of Flos Magnoliae volatile oil nano-liposome nasal drops (FMO) in treating pediatric allergic rhinitis (PAR).

METHODSAdopting parallel controlled method, the 191 patients with PAR were randomized into two groups. The observation group was treated with FMO, and the control group with Cetirizine. The clinical efficacy, main symptoms, signs, syndromes scores of Chinese medicine, and peripheral eosinophil (EOS) count were observed after 3-week treatment.

RESULTSIn the observation group, the total effective rate was 94.84%, which was higher than that in the control group (78.72%); the effective rate on alleviating main symptoms (sneezing, nasal obstruction), signs (nasal mucosa edema, pallor) and the EOS count were significantly lowered, all were better than those in the control group (P <0.05).

CONCLUSIONFMO has some positive effects on PAR, it might be realized by lowering the peripheral EOS.

Child ; Child, Preschool ; Drugs, Chinese Herbal ; Eosinophils ; Female ; Humans ; Liposomes ; therapeutic use ; Male ; Oils, Volatile ; therapeutic use ; Phytotherapy ; Rhinitis, Allergic, Perennial ; drug therapy ; Rhinitis, Allergic, Seasonal ; drug therapy ; Treatment Outcome

OBJECTIVE: To investigate the effects of prophylactic drugs on allergic rhinitis. METHOD: Thirty patients diagnosed as allergic rhinitis based on mugwort allergen were randomly divided into three groups: budesonide group (n = 10), saline group (n = 10) and control group (n = 10). The patients in budesonide group and saline group respectively received budesonide nasal spray (64 microg per, 256 microg once daily) and saline nasal spray twice daily starting two weeks before the date which the patient onset last year and continuing up to the end of the pollen season. The patients in control group were treated without any processing. The nasal symptom scores and attack times of the three groups was recorded. RESULT: During the pollen season, 2 patients attacked in the budesonide group (20%), and all the patients attacked in saline group and control group (100%). Statistical significance was found among the three groups (P < 0.01), and between budesonide group and the other two groups (P < 0.01). The budesonide group had lower symptom score than the other two groups and a postponed attack time. All the differences had Statistical significance (Value of chi-square statistic = 21. 558, P < 0.01, Fisher exact test P < 0.01). CONCLUSION Prophylactic administration of budesonide, starting two weeks before the date which the patient onset may release symptom and even avoid the attack of the allergic rhinitis based on mugwort allergen.
Adolescent ; Adult ; Aged ; Anti-Inflammatory Agents ; therapeutic use ; Budesonide ; therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Pollen ; Rhinitis, Allergic, Seasonal ; drug therapy ; immunology ; prevention & control ; Young Adult

OBJECTIVE: To evaluate the efficacy and safety of Aerius to seasonal allergic rhinitis. METHOD: Using randomized, controlled method, treatment group 40 cases, oral administration Aerius 5 mg/d for 12 days; control group 35 cases, oral administration Aerius 5 mg/d for 12 days, investigating their efficacy and safety. RESULT: The total effective rate of treatment group was 92.50%, while control group was 85.71%, there was significant difference between them (P<0.05). Significant improvements of seasonal allergic rhinitis nasal obstruction were seen in treatment group after using Aerius (P<0.05). The incidence of side effect of treatment group was 2.50%. CONCLUSION Aerius is safe and can effectively reduction in nasal and nonnasal symptoms in patients with seasonal allergic rhinitis.
Adolescent ; Adult ; Anti-Allergic Agents ; adverse effects ; therapeutic use ; Child ; Female ; Histamine H1 Antagonists ; adverse effects ; therapeutic use ; Humans ; Loratadine ; adverse effects ; analogs & derivatives ; therapeutic use ; Male ; Middle Aged ; Rhinitis, Allergic, Seasonal ; drug therapy ; Treatment Outcome ; Young Adult

Administration, Intranasal ; Adult ; Aerosols ; Androstadienes ; therapeutic use ; Anti-Inflammatory Agents ; administration & dosage ; therapeutic use ; Budesonide ; therapeutic use ; Child ; Female ; Fluticasone ; Humans ; Male ; Mometasone Furoate ; Nasal Polyps ; drug therapy ; Pregnadienediols ; therapeutic use ; Rhinitis, Allergic, Perennial ; drug therapy ; epidemiology ; pathology ; Rhinitis, Allergic, Seasonal ; drug therapy ; Singapore ; epidemiology ; Sinusitis ; drug therapy ; Triamcinolone Acetonide ; therapeutic use

OBJECTIVE: To evaluate the effects of nasal mometasone furoate on oral and nasal nitric oxide (NO) production in patients with allergic rhinitis. METHOD: Twenty-seven patients with moderate to severe symptoms of persistent allergic rhinitis were treated with mometasone furoate nasal spray (200 microg/d. qd) for 2 weeks. Nasal and oral exhaled nitric oxide concentrations, symptoms of rhinitis and quality of life were investigated before and after the treatment. RESULT: There was a significant improvement in nasal exhaled nitric oxide concentrations, symptoms of rhinitis and quality of life, but not in oral exhaled nitric oxide concentrations. Subjective improvements in symptoms and quality of life did not correlate significantly with objective measurements. CONCLUSION Our study provides subjective and objective evidence on the efficacy of intranasal mometasone furoate in improving nasal symptoms and quality of life, as well as reducing nasal inflammation.
Administration, Intranasal ; Adolescent ; Adult ; Anti-Allergic Agents ; administration & dosage ; therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Mometasone Furoate ; Nitric Oxide ; metabolism ; Pregnadienediols ; administration & dosage ; therapeutic use ; Quality of Life ; Rhinitis, Allergic, Perennial ; drug therapy ; metabolism ; physiopathology ; Rhinitis, Allergic, Seasonal ; drug therapy ; metabolism ; physiopathology ; Young Adult

OBJECTIVE: To compare the efficacy and safety of histamine H1 receptor antagonist loratadine with Leukotriene receptor antagonist Ibudilast in steroid resistant allergic rhinitis in a randomized controlled clinical trial. METHOD: Thirty-five cases were treated by Ibudilast, and 34 cases by loratadine. Score system was used to compare the therapeutic effect of these two drugs on clinical symptoms and signs. RESULT: Ibudilast shows a better curative effect than loratadine in the improvement of the total scores on clinical symptom and signs(P<0.05). Scores of symptoms and signs in Ibudilast group after 3, 7, 14 days decreased significantly by means of square analysis of single factor (P<0.01). No complication was observed. CONCLUSION Ibudilast can effectively alleviate the clinical symptoms and signs of steroid resistant allergic rhinitis with confirmed efficacy and safety, thus is recommended in steroid resistant allergic rhinitis. Increased doses or prolonged treatment of steroid is inappropriate.
Adolescent ; Adult ; Aged ; Anti-Allergic Agents ; therapeutic use ; Female ; Histamine H1 Antagonists, Non-Sedating ; therapeutic use ; Humans ; Leukotriene Antagonists ; therapeutic use ; Loratadine ; therapeutic use ; Male ; Middle Aged ; Pyridines ; therapeutic use ; Rhinitis, Allergic, Perennial ; drug therapy ; Rhinitis, Allergic, Seasonal ; drug therapy ; Steroids ; pharmacology ; Young Adult